Active Genetics & Molecular Biology Brain & Nervous System

New horizons in Mendelian randomization

In plain English

AI plain-English summary

A single genetic variant can act like a random coin flip, letting researchers test whether a specific factor truly causes a disease—without needing to run a slow, expensive clinical trial. This matters because standard observational studies are easily fooled by hidden biases like lifestyle or socioeconomic factors, while randomised trials are often too costly or impractical to run for every possible exposure. Mendelian randomisation (MR) exploits the natural lottery of genetics to mimic a trial, giving faster, more reliable answers about what actually drives health outcomes. If this research succeeds, drug developers and policymakers will know not just *whether* a factor causes disease, but *how* it does so, *when* intervening works best, and *which* population groups benefit most. That could mean targeting the right biological mechanism in the right people at the right time—shortening the path from genetic clue to effective treatment. The team will also provide tools and training so other researchers can apply these methods to their own questions, widening the impact beyond the immediate projects.

View original technical description
When considering whether an exposure is a causal risk factor for an outcome, evidence from randomized trials is reliable but typically slow or impractical to gather, whereas evidence from conventional observational studies is often unreliable, as it is subject to bias from confounding and reverse causation. Mendelian randomization (MR) is an example of a quasi-experimental approach: it is analogous to a randomized trial, but relies on nature doing the randomization for us. MR can be implemented rapidly for a range of exposures to provide insights about causal relationships that can prioritize or deprioritize exposures for further investigation. The aim of our research is to develop methods that enable detailed MR analyses to inform policymakers and drug developers about the nature of causal effects: enabling trial interventions to target the right mechanism in the right population group at the right time. We will develop methodology for MR that informs us on how causal effects occur, when interventions are most effective, and which population groups they are strongest in. We will also apply our methods to address questions of key biomedical importance, and provide resources and training so that others can apply our methods to their research questions.

View the original record at the funder ↗

Researchers

Stephen Burgess (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Mendelian Randomisation
Integration of causal evidence from Mendelian randomization and randomised controlled trials to inform drug discovery for human diseases.
Mendelian randomization to hypothesis-free causal inference
Identifying causal effects sizes in population genetics via Mendelian randomisation
Developing cross-population Mendelian randomization for generalizing evidence on drug targets: the MRC Cross-Population Mendelian Randomization Network

Original classification

Career Development Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.